- Home
- OCX vs RNXT Comparison
OCX vs RNXT Comparison
Compare OCX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- RNXT
- Stock Information
- Founded
- OCX 2009
- RNXT 2012
- Country
- OCX United States
- RNXT United States
- Employees
- OCX N/A
- RNXT N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- OCX Health Care
- RNXT Health Care
- Exchange
- OCX Nasdaq
- RNXT Nasdaq
- Market Cap
- OCX 35.1M
- RNXT 31.6M
- IPO Year
- OCX N/A
- RNXT 2021
- Fundamental
- Price
- OCX $2.80
- RNXT $1.08
- Analyst Decision
- OCX Buy
- RNXT Strong Buy
- Analyst Count
- OCX 3
- RNXT 1
- Target Price
- OCX $4.42
- RNXT $9.00
- AVG Volume (30 Days)
- OCX 85.7K
- RNXT 213.4K
- Earning Date
- OCX 04-11-2025
- RNXT 03-31-2025
- Dividend Yield
- OCX N/A
- RNXT N/A
- EPS Growth
- OCX N/A
- RNXT N/A
- EPS
- OCX N/A
- RNXT N/A
- Revenue
- OCX $709,000.00
- RNXT N/A
- Revenue This Year
- OCX N/A
- RNXT N/A
- Revenue Next Year
- OCX $106.34
- RNXT N/A
- P/E Ratio
- OCX N/A
- RNXT N/A
- Revenue Growth
- OCX N/A
- RNXT N/A
- 52 Week Low
- OCX $1.92
- RNXT $0.77
- 52 Week High
- OCX $3.48
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- OCX 69.99
- RNXT 34.68
- Support Level
- OCX $2.21
- RNXT $1.00
- Resistance Level
- OCX $2.80
- RNXT $1.10
- Average True Range (ATR)
- OCX 0.22
- RNXT 0.09
- MACD
- OCX 0.08
- RNXT -0.04
- Stochastic Oscillator
- OCX 89.95
- RNXT 12.00
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.